Cue Biopharma corrects director RSU grant to 18.9K

Cue Biopharma, Inc. (CUE) reports an amended Form 4 for director Pamela Garzone to correct a prior administrative calculation error in a grant of restricted stock units (RSUs).

Rhea-AI Filing Summary

Cue Biopharma, Inc. (CUE) reports an amended Form 4 for director Pamela Garzone to correct a prior administrative calculation error in a grant of restricted stock units (RSUs). The original report showed 21,800 shares acquired; the correct amount is 18,900 shares, which is now also the total beneficially owned following the transaction. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to her continued service with the company.

Insider Trade Summary

Grant/Award: 18,900 shares

Grant/Award 1 txn

Insider Garzone Pamela

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	18,900	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,900 shares (Direct)

Footnotes (1)

1. F1. This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date.

Key Figures

Correct RSUs acquired: 18,900 shares Originally reported RSUs: 21,800 shares Total securities beneficially owned after transaction: 18,900 shares +3 more

6 metrics

Correct RSUs acquired 18,900 shares Grant of restricted stock units to Pamela Garzone on 2026-07-09

Originally reported RSUs 21,800 shares Amount incorrectly reported in the original Form 4

Total securities beneficially owned after transaction 18,900 shares Column 5 total after correction

Vesting date 1 July 9, 2027 One-third of RSU grant vests, subject to continued service

Vesting date 2 July 9, 2028 One-third of RSU grant vests, subject to continued service

Vesting date 3 July 9, 2029 Final one-third of RSU grant vests, subject to continued service

Key Terms

restricted stock units, beneficially owned, continued service

3 terms

restricted stock units financial

"relating to a grant of restricted stock units ("RSUs") to the Reporting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficially owned financial

"the total amount of securities beneficially owned following the reported"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

continued service financial

"subject to the Reporting Person's continued service with the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change does this amended Form 4/A report for CUE?

The amendment corrects an earlier error in a restricted stock unit grant to director Pamela Garzone. The original filing reported 21,800 shares acquired; the correct number is 18,900 shares, which is now also the total beneficially owned after the transaction.

How many Cue Biopharma (CUE) shares did Pamela Garzone actually acquire?

Pamela Garzone acquired 18,900 shares of Cue Biopharma common stock through a restricted stock unit grant. This corrects a prior overstatement that had shown 21,800 shares acquired.

What is Pamela Garzone’s total CUE beneficial ownership after this correction?

After the correction, Pamela Garzone is reported to beneficially own a total of 18,900 Cue Biopharma shares, all from the corrected restricted stock unit grant.

How do the Cue Biopharma (CUE) RSUs granted to Pamela Garzone vest?

The RSUs granted to Pamela Garzone vest in three equal installments. One-third vests on July 9, 2027, one-third on July 9, 2028, and one-third on July 9, 2029, subject to her continued service with Cue Biopharma.

Was the CUE Form 4/A related to a new transaction or an error correction?

The Form 4/A relates to an error correction. It amends a prior report to fix an administrative calculation error that overstated the number of RSUs granted to Pamela Garzone, revising it from 21,800 to 18,900 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 05:05 PM EDT Accepted by SEC EDGAR 08/28/2026 - 05:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garzone Pamela

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/10/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		18,900(1)	A	$0	18,900	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date.

	/s/ Michael Meluzio, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)